Eli Lilly's Retevmo Receives Regulatory Approval for Marketing in China

Stock News

Yesterday

On September 18th, the National Medical Products Administration (NMPA) website announced the market approval of Eli Lilly's (LLY.US) new class 5.1 drug, "Selpercatinib tablets," in China. Public information indicates this marks the first approval for the tablet formulation of Selpercatinib within the country.

Selpercatinib is a first-in-class, highly selective, and potent small-molecule RET inhibitor characterized by central nervous system (CNS) activity. Its mechanism enables the inhibition of multiple RET alterations, functioning by suppressing the activity of aberrant RET kinases. As the first highly selective RET inhibitor approved globally, this drug represents a significant advancement in targeted therapy.

The approval underscores Eli Lilly's continued commitment to expanding patient access to innovative oncology treatments, with the NMPA's decision paving the way for domestic availability of this targeted therapy option.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/news/1164894808"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164894808\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164894808?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164894808","market":"fut","top_or_hot":-1,"title":"Eli Lilly's Retevmo Receives Regulatory Approval for Marketing in China","media":"Stock News","content":"<p>On September 18th, the National Medical Products Administration (NMPA) website announced the market approval of Eli Lilly's (LLY.US) new class 5.1 drug, \"Selpercatinib tablets,\" in China. Public information indicates this marks the first approval for the tablet formulation of Selpercatinib within the country.<br><br>Selpercatinib is a first-in-class, highly selective, and potent small-molecule RET inhibitor characterized by central nervous system (CNS) activity. Its mechanism enables the inhibition of multiple RET alterations, functioning by suppressing the activity of aberrant RET kinases. As the first highly selective RET inhibitor approved globally, this drug represents a significant advancement in targeted therapy.<br><br>The approval underscores Eli Lilly's continued commitment to expanding patient access to innovative oncology treatments, with the NMPA's decision paving the way for domestic availability of this targeted therapy option.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly's Retevmo Receives Regulatory Approval for Marketing in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly's Retevmo Receives Regulatory Approval for Marketing in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-18 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On September 18th, the National Medical Products Administration (NMPA) website announced the market approval of Eli Lilly's (LLY.US) new class 5.1 drug, \"Selpercatinib tablets,\" in China. Public information indicates this marks the first approval for the tablet formulation of Selpercatinib within the country.<br><br>Selpercatinib is a first-in-class, highly selective, and potent small-molecule RET inhibitor characterized by central nervous system (CNS) activity. Its mechanism enables the inhibition of multiple RET alterations, functioning by suppressing the activity of aberrant RET kinases. As the first highly selective RET inhibitor approved globally, this drug represents a significant advancement in targeted therapy.<br><br>The approval underscores Eli Lilly's continued commitment to expanding patient access to innovative oncology treatments, with the NMPA's decision paving the way for domestic availability of this targeted therapy option.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"","article_id":"1164894808","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164894808","pubTimestamp":1789737638,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On September 18th, the National Medical Products Administration (NMPA) website announced the market approval of Eli Lilly's (LLY.US) new class 5.1 drug, \"Selpercatinib tablets,\" in China. Public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPOS":"Renaissance International IPO ETF"},"translate_title":"礼来的 Retevmo 获得监管部门批准在中国上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1},"content_text":"On September 18th, the National Medical Products Administration (NMPA) website announced the market approval of Eli Lilly's (LLY.US) new class 5.1 drug, \"Selpercatinib tablets,\" in China. Public information indicates this marks the first approval for the tablet formulation of Selpercatinib within the country.Selpercatinib is a first-in-class, highly selective, and potent small-molecule RET inhibitor characterized by central nervous system (CNS) activity. Its mechanism enables the inhibition of multiple RET alterations, functioning by suppressing the activity of aberrant RET kinases. As the first highly selective RET inhibitor approved globally, this drug represents a significant advancement in targeted therapy.The approval underscores Eli Lilly's continued commitment to expanding patient access to innovative oncology treatments, with the NMPA's decision paving the way for domestic availability of this targeted therapy option.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}